Highlights Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Market Closed - Nasdaq Stockholm Other stock markets 16:29:59 17/05/2024 BST			5-day change	1st Jan Change
36.8 ^SEK	-4.17%		+11.52%	+2.79%

05-08	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-15	Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	01-31	CI
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	01-15	CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	28/09/23	CI
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	19/09/23	CI
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA	14/07/23	CI
Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation	14/06/23	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Guard Therapeutics Provides Updated Information on the Phase 2 Study AKITA	02/05/23	CI
Guard Therapeutics International AB Presents Positive Clinical Data with RMC-035 in Patients Undergoing Kidney Transplantation	16/03/23	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	22/02/23	CI
Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA	16/02/23	CI
Guard Therapeutics International AB Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial	10/02/23	CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	16/11/22	CI
Guard Therapeutics International AB Receives FDA Fast Track Designation for RMC-035	08/11/22	CI
Guard Therapeutics International AB Receives IND Approval from the FDA for RMC-035	10/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Highlights

Filters